Mylan Launches Generic Reclast(R) Injection

HERTFORDSHIRE, England and PITTSBURGH, June 2, 2017 -- (Healthcare Sales & Marketing Network) -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the U.S. launch of Zoledronic Acid Injection, 5 mg/100 mL Single Dose Vial, a generic version of Novartis' Recl... Biopharmaceuticals, Generics, FDA, Product Launch Mylan, Zoledronic Acid, Reclast, Paget's disease
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news